Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PXVX0317 (Vimkunya) in Healthy Adults
NCT05065983Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CHIKV VLP vaccine in Chikungunya (CHIKV), sponsored by Bavarian Nordic. Started Oct 2021; status: completed.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT05065983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065983.